BioScrip (BIOS) Trading 10.5% Higher

Share on StockTwits

BioScrip Inc (NASDAQ:BIOS)’s share price traded up 10.5% during trading on Monday . The company traded as high as $2.12 and last traded at $2.10. 3,081,050 shares traded hands during mid-day trading, an increase of 151% from the average session volume of 1,226,480 shares. The stock had previously closed at $1.90.

A number of equities analysts recently commented on the company. BidaskClub downgraded BioScrip from a “buy” rating to a “hold” rating in a report on Thursday, January 17th. Canaccord Genuity decreased their target price on BioScrip from $5.00 to $3.50 and set a “buy” rating for the company in a research report on Monday, March 18th. Zacks Investment Research cut BioScrip from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. TheStreet raised BioScrip from a “d+” rating to a “c-” rating in a research report on Monday, November 26th. Finally, Stephens cut BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 target price for the company. in a research report on Monday, March 18th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $4.70.

The stock has a market capitalization of $243.49 million, a PE ratio of -4.29 and a beta of 0.76.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Friday, March 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.11). The business had revenue of $183.57 million during the quarter, compared to analysts’ expectations of $188.39 million. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.03) earnings per share. On average, sell-side analysts anticipate that BioScrip Inc will post -0.22 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC boosted its position in shares of BioScrip by 13.7% in the fourth quarter. Squarepoint Ops LLC now owns 52,389 shares of the company’s stock valued at $187,000 after acquiring an additional 6,303 shares during the period. Virtu Financial LLC boosted its position in shares of BioScrip by 60.6% in the fourth quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock valued at $65,000 after acquiring an additional 6,868 shares during the period. Maven Securities LTD bought a new stake in shares of BioScrip in the fourth quarter valued at approximately $45,000. Caxton Associates LP bought a new stake in shares of BioScrip in the fourth quarter valued at approximately $52,000. Finally, Royce & Associates LP boosted its position in shares of BioScrip by 1.1% in the fourth quarter. Royce & Associates LP now owns 2,228,500 shares of the company’s stock valued at $7,956,000 after acquiring an additional 24,500 shares during the period. 82.51% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/4248579/bioscrip-bios-trading-10-5-higher.html.

BioScrip Company Profile (NASDAQ:BIOS)

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Featured Story: Fiduciary

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Anticipate Caretrust REIT Inc  Will Post Quarterly Sales of $41.13 Million
Zacks: Analysts Anticipate Caretrust REIT Inc Will Post Quarterly Sales of $41.13 Million
Apollo Currency  Price Hits $0.0015
Apollo Currency Price Hits $0.0015
Central Pacific Financial  Releases  Earnings Results, Beats Estimates By $0.03 EPS
Central Pacific Financial Releases Earnings Results, Beats Estimates By $0.03 EPS
Republic First Bancorp  Sets New 52-Week Low at $5.01
Republic First Bancorp Sets New 52-Week Low at $5.01
Inphi Co.  VP Sells $434,039.87 in Stock
Inphi Co. VP Sells $434,039.87 in Stock
Allegion  Issues Quarterly  Earnings Results
Allegion Issues Quarterly Earnings Results


© 2006-2019 Ticker Report